Immune Repertoire Sequencing The New Standard In Cancer Drug Research

Novel approaches in oncology include delivery of the gene of interest and expression of antigens within a host, development of targeted therapies, immunotherapies and early diagnosis of cancer. Immune repertoire sequencing is seen as a promising approach that can help to device immunological response against cancer. Immune repertoire sequencing can also help in the development of personalized vaccines as the technology has led the way for the identification of unique therapeutic targets and cancer biomarkers. Global immune repertoire sequencing projected to grow at a CAGR of 8% over the forecast period of 2019-2026. The market for Immune repertoire sequencing is primarily driven due to rising number of cancer cases globally. According to the American Cancer Society, cancer accounted for 16% of global deaths (a total of 8.9 million) in 2015. By 2030, the American Cancer Society anticipates that the number of deaths due to cancer is likely to reach 23.9 million, a fact which will prompt requirements for effective investigative tools and treatment regimens for containing mortality.

To have a brief overview of the report please click on the following link

http://www.briskinsights.com/report/immune-repertoire-sequencing-market

High funding for disease Research to drive the Immune repertoire sequencing market

According to the WHO, the number of patients suffering from chronic diseases such as cancer, chronic respiratory diseases and cardiovascular diseases was about 130 million in 2005 and is expected to reach around 173 million by 2030. Both public and private organizations are looking to fund the development of new treatment and therapy systems in order to develop an effective treatment regime to fight chronic diseases. The National Institutes of Health (NIH, U.S.) in co-ordination with the Centers for Disease Control and Prevention, proposed funding for various domains within cell biology with the aim to develop new effective treatment regimes, analytical instruments and real-time monitoring. The immune repertoire sequencing is majorly benefitted with these high funding for disease research.  As per the official data released by NIH, the NIH has spent a total of $2.00 trillion in 2018 for research of various disease and condition including cancer, CVD, autoimmune diseases and others. National Science Foundation (NSF) funding for molecular and cellular biosciences and integrative orgaismal systems in 2017 was reported to be around $137 million and $215.63 million respectively, with research funding anticipated to be increased by 2% per annum. Likewise, the European Commission announced spending of over $120 billion for biological science research between 2021 and 2027, with focus on both cellular- and molecular-level treatment and diagnostics. These investments are likely to lead way for the growth of immune repertoire sequencing market.